Can't Kick the Bud? Achieve's Cytisinicline Proves Promising in Phase 3 Smoking Cessation Trial
Portfolio Pulse from Vandana Singh
Achieve Life Sciences announced positive topline results from the Phase 3 ORCA-3 trial of cytisinicline, showing statistically significant benefits in helping people quit smoking compared to placebo. The 6- and 12-week treatment durations demonstrated significant smoking cessation rates.
May 23, 2023 | 4:46 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Achieve Life Sciences' cytisinicline demonstrated significant success in the Phase 3 ORCA-3 trial, potentially leading to increased demand for the smoking cessation treatment.
The positive results from the Phase 3 ORCA-3 trial indicate that cytisinicline is effective in helping people quit smoking. This could lead to increased demand for the treatment, which would benefit Achieve Life Sciences' business and potentially drive up the stock price. However, the stock is currently down 20.50% at $6.48.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100